Safety Study of Stemchymal® in Acute Liver Failure
Phase 1
Withdrawn
- Conditions
- Acute Liver FailureSteminentStem CellsAdult Stem CellsAcute-On-Chronic Liver Failure
- Interventions
- Biological: Stemchymal®
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Steminent Biotherapeutics Inc.
- Registration Number
- NCT03629015
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee
Phase 1
Completed
- Conditions
- Osteoarthritis Knee
- Interventions
- Drug: Adipose-Derived Mesenchymal Stem Cells
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Steminent Biotherapeutics Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02544802
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia
Phase 2
Completed
- Conditions
- Cerebellar Ataxia
- Interventions
- Biological: Stemchymal®Procedure: Excipients
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Steminent Biotherapeutics Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT02540655
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath